.png?sfvrsn=1a7df424_2)
Our Capabilities
CHO CELL GENOME EDITING AND EXPRESSION MODIFICATION
Using ZFNs, TALENS, CRISPR/Cas9 editing and RNA interference for boosting CHO lifespan, higher viable cell densities, productivity, and efficacy.
FUNCTIONAL STUDIES OF GLYCOSYLATION GENES
For streamlined glycoengineering efforts in key mammalian cell lines (e.g. CHO, HEK293, BHK, 3T3, NS0, Cos-7 etc.).
GLYCOENGINEERED CHO MUTANT CELL PANEL
Production of novel food associated oligosaccharide.
PRODUCTION OF ANTIBODY AND RECOMBINANT PROTEIN THERAPEUTICS WITH HOMOGENOUS N-GLYCANS
Enhance drug efficacy, suitable for chemical modifications such as generating ADCs.
Our deep experiences in glycoengineering facilitates success in protein production, particularly in view of protein glycosylation’s complexity, where more than 600 genes are estimated to be involved, compounded further by bioprocessing variability and industrial practicality.
Our Technologies
GLYCOENGINEERING FOR PRODUCTION OF ANTIBODY AND RECOMBINANT PROTEIN THERAPEUTICS WITH HOMOGENOUS N-GLYCANS
CHO-gmt3 produced fucose-free antibody rituximab which killed cancer cells much more efficiently than commercial rituximab (MabThera)
GS-CHO system for biologics production
Comparison of attenuated GS R324C with GS wild type (WT) and with MSX for the stable production of mAb. (A) Antibody titer measurement of independently transfected stable cell pools. Stability assessment of mAb production over 8 weeks(>60 generations) of single clones generated by (B) GS WT+MSX and (C) GS R324C selection.
OUR TRACK RECORD
Featured Publications
- Pao-Chun Lin, Ren Liu, Krista Alvin, Shahreel Wahyu, Nicholas Murgolo, Jianxin Ye, Zhimei Du and Zhiwei Song (2021) Improving Antibody Production in Stably Transfected CHO Cells by CRISPR-Cas9-Mediated Inactivation of Genes Identified in a Large-Scale Screen with Chinese Hamster-Specific siRNAs. Biotechnology Journal 16(3):e2000267
- Sandra Prior, Aghiles Boughetane, Bernard Fox, Melissa Hayman, Eleanor Atkinson, Peter Rigsby, Meenu Wadhwa and Simon Hufton, and participants in the collaborative study (2020) Report on a Collaborative Study for Proposed Candidate 1st International Standard for the biological activities of Trastuzumab. WHO/BS/2020.2401
- Pao-Chun Lin, Kah Fai Chan, Irene A Kiess, Joselyn Tan, Wahyu Shahreel, Sze-Yue Wong and Zhiwei Song (2019) Attenuated glutamine synthetase as selection marker in CHO cells to efficiently isolate highly productive stable cells for production of antibodies and other biologics. mAbs 11(5):965-976
- Kah Fai Chan, Wahyu Shahreel, Corrine Wan, Gavin Teo, Noor Hayati, Shi Jie Tay, Wen Han Tong, Yuansheng Yang, Pauline M Rudd, Peiqing Zhang and Zhiwei Song (2016) Inactivation of GDP-fucose transporter gene (Slc35c1) in CHO cells by ZFNs, TALENs and CRISPR-Cas9 for production of fucose-free antibodies. Biotechnology Journal 11(3):399-414
- John S Y Goh, Peiqing Zhang, Kah Fai Chan, May May Lee, Sing Fee Lim and Zhiwei Song (2010) RCA-I-resistant CHO mutant cells contain dysfunctional GnT I and expression of GnT I in these mutants enhances sialylation of recombinant erythropoietin. Metabomic Engineering 12(4):360-368
Landmark Patent & IP:
- Attenuated glutamine synthetase as a selection marker (2018)
- Optimised heavy chain and light chain signal peptides for the production of recombinant antibody therapeutics (2014)
- Method of producing recombinant proteins with mannose-terminated N-glycans (2011)
- Chinese hamster ovary cell linesGnT I mutant CHO cell lines (2009)
The Team
Dr Song Zhiwei
song_zhiwei@bti.a-star.edu.sg
Senior Principal Scientist II
PhD in Biochemistry (1993) University of Michigan, Ann Arbor, USA
Research Focus / Interest
- Glycosylation of recombinant protein drugs
- Apoptosis in cultured mammalian cells
- Developing cell lines to produce follow-on biologics such as therapeutic antibodies
Dr Wang Huashan
wang_huashan@bti.a-star.edu.sg
Senior Scientist II
PhD in Molecular genetics (2006), Yong Loo Lin School of Medicine, National University of Singapore, Singapore
Research Focus / Interest
- Expression of anticancer antibodies in cell lines
- Development of cell lines for the production of therapeutic antibodies
Dr Chan Kah Fai
chan_kah_fai@bti.a-star.edu.sg
Senior Scientist I
PhD in Biochemistry (2017), Yong Loo Lin School of Medicine, National University of Singapore
Research Focus / Interest
- Genetic engineering of novel CHO cell lines for industrial manufacturing of biologics
- Applications of BTI CHO glycosylation mutant cell lines for production of alternative biomolecules
- Recombinant fusion proteins and antibodies for therapeutic application
